Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several mechanistic/clinical claims about vitamins (K, D, B12) and interactions/supplementation are not supported by the provided LIPITOR label excerpts. While some general statin-related lipid and cardiovascular risk reduction statements align with the label, multiple specific vitamin-related and bleeding-risk claims lack label support, lowering overall alignment.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication that works by inhibiting the production of cholesterol in the liver.
Label section 12.1 Mechanism of Action: selective competitive inhibitor of HMG-CoA reductase.
Lipitor lowers low-density lipoprotein (LDL) cholesterol levels.
Label section 14.2: reduces LDL-C; section 1.2: adjunct to diet to reduce LDL-C.
Lipitor can help reduce the risk of heart disease and stroke.
Label section 1.1 Prevention of Cardiovascular Disease: reduces risk of myocardial infarction and stroke.
Unsupported Statements
Lipitor can interfere with the absorption of certain vitamins.
No vitamin absorption-interference statement appears in the provided label excerpts.
Statins, including Lipitor, can decrease the production of vitamin K-dependent proteins in the liver.
No vitamin K-dependent proteins mechanism is stated in the provided label excerpts.
Decreased production of vitamin K-dependent proteins in the liver leads to a decrease in vitamin K levels.
No label support for vitamin K level reduction mechanism.
In a study, patients taking Lipitor experienced a significant decrease in vitamin K levels.
No vitamin K study result appears in the provided label excerpts.
A decrease in vitamin K levels associated with taking Lipitor was associated with an increased risk of bleeding.
No label support linking Lipitor-associated vitamin K decrease to bleeding risk.
Vitamin K is essential for the production of clotting factors in the blood.
No such vitamin K physiology claim appears in the provided label excerpts.
A vitamin K deficiency can lead to easy bruising and bleeding.
No such vitamin deficiency clinical effects statement appears in the provided label excerpts.
Some research suggests statins, including Lipitor, may decrease vitamin D levels by inhibiting the production of vitamin D in the skin.
No vitamin D mechanism or level decrease is stated in the provided label excerpts.
Patients taking statins, including Lipitor, were more likely to experience vitamin B12 deficiency.
No vitamin B12 deficiency association is stated in the provided label excerpts.
Taking Lipitor and vitamins can increase the risk of bleeding and other adverse effects.
The provided label excerpts discuss bleeding signal in the context of hemorrhagic stroke at 80 mg, but do not support a general claim about 'taking Lipitor and vitamins' increasing bleeding risk.
Regular blood tests can check vitamin levels and help adjust a supplement regimen accordingly.
No label recommendation to monitor vitamin levels or adjust supplements based on vitamins is included in the provided excerpts.
Taking vitamins at a different time of day than Lipitor may minimize interactions between Lipitor and vitamins.
No label statement about timing separation to prevent interactions with vitamins/supplements is provided in the excerpts.
Contradictions
Important Omissions
If evaluating bleeding risk claims, the label excerpt provided only supports that a post-hoc analysis showed higher incidence of hemorrhagic stroke with LIPITOR 80 mg vs placebo; it does not support vitamin-K/vitamin-supplement related bleeding mechanisms described in the response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported vitamin/vitamin-monitoring and bleeding-risk linkage claims could lead to inappropriate focus on unlabelled monitoring/supplement timing rather than label-supported safety monitoring (e.g., liver tests; myopathy vigilance) and management. The response does not directly contradict core contraindications, but it introduces multiple unsupported safety-related assertions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple specific vitamin-K, vitamin-D, and vitamin-B12 claims and supplement-interaction/bleeding/monitoring recommendations are not supported by the supplied LIPITOR label excerpts.
Suggested Improvement
Limit claims to label-supported information in the excerpts (e.g., LDL-C lowering; cardiovascular risk reduction; administered once daily with or without food; contraindications such as pregnancy/active liver disease; label-supported warnings such as myopathy/rhabdomyolysis and liver enzyme monitoring; label-supported drug interactions such as strong CYP3A4 inhibitors/clarithromycin and grapefruit). Remove unlabelled vitamin K/D/B12 and timing/monitoring assertions unless supported by the provided label text.